Bisocor

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisocor

Bisocor is a prescription-only medication whose identity is rooted in its active ingredient, Bisoprolol Fumarate. It is utilized to support the stable performance of the heart and the regulation of high pressure within the circulatory system.

Property Description
Active Ingredient Bisoprolol Fumarate
Form Oral Tablet (typically film-coated)
Pharmacological Class Beta-blocker (Cardioselective beta1-Antagonist)
Origin Synthetic (Chemically Synthesized)
Product Type Single-ingredient product

Pharmacological Class and Composition

Bisocor is a medicine classified as a beta-blocker, or formally, an adrenergic beta-antagonist. This places it within a category of drugs that specifically modulate the effects of stimulating hormones, such as adrenaline, on the cardiovascular system. The active substance, Bisoprolol Fumarate, is a synthetic compound, produced via chemical synthesis. It is generally provided as a single-ingredient product in an oral tablet form, prepared for systemic action after oral administration.

Core Functional Principle

The drug is recognized for its cardioselectivity, meaning it primarily targets the beta1 adrenergic receptors concentrated in the heart muscle. This characteristic helps to focus its action on the cardiac system, differentiating it from non-selective agents. The general purpose of Bisocor is to apply a principle of workload reduction on the heart muscle. By selectively blocking the signals from stress hormones, the drug reduces the heart's frequency (a negative chronotropic effect) and decreases the force of its contractions, allowing for a more efficient and moderated cardiovascular response. A typical neutral use scenario for Bisocor involves long-term supportive therapy for patients managing elevated systemic pressure.

Regulatory References

  1. Bisoprolol Fumarate Label (DailyMed)

What side effects are possible with Bisocor?

Possible Side Effects and Safety Information

The safety profile of Bisocor (Bisoprolol Fumarate) is defined by officially documented adverse reactions classified by incidence and the body systems they affect, based on regulatory labeling.

Frequency-Classified Adverse Reactions

Adverse effects are categorized according to how often they may occur:

  • Very Common: Slowed heart rate (bradycardia), specifically noted in patients treated for chronic heart failure.
  • Common: Dizziness, headache, fatigue, asthenia, a sensation of coldness or numbness in the hands and feet, and gastrointestinal disturbances such as nausea, vomiting, diarrhea, and constipation.
  • Uncommon: Further disturbances in the heart’s electrical conduction, worsening of pre-existing heart failure, and bronchospasm (especially in patients with a history of asthma or COPD).
  • Rare: Depression, sleep disturbances (including nightmares), elevated liver enzymes (ALT, AST), hepatitis, and hypersensitivity reactions like rash or itching.

Safety Considerations and Restrictions

The regulatory profile identifies specific safety considerations related to patient health status and timing of exposure. Certain effects, including dizziness and headache, are often more frequent at the start of treatment or during dose titration. The medicine is formally contraindicated in conditions such as acute heart failure, cardiogenic shock, and severe bronchial asthma.

Specific caution is noted for certain patient groups, including individuals with diabetes mellitus (due to the potential to mask symptoms of low blood sugar) and those with hepatic or renal impairment (which may necessitate careful monitoring).

Overdose and Emergency Response

An overdose of Bisocor (Bisoprolol Fumarate) is documented in regulatory labeling as a potentially severe event that requires immediate medical intervention. Officially reported manifestations center on cardiovascular and neurological depression.

Documented Overdose Manifestations

Overdose may present with critical signs such as marked bradycardia (abnormally slow heart rate) and pronounced hypotension (abnormally low blood pressure), often leading to shock or overt cardiac failure. Documented central nervous system effects include drowsiness, confusion, seizures, and coma. Respiratory compromise, evidenced by wheezing and difficulty breathing, is also an officially noted presentation. The risk of these severe outcomes is increased with co-ingestion of other cardiac agents. A specific concern documented in official information is severe hypoglycemia (low blood sugar), which is common in the pediatric population following ingestion.

When to Seek Immediate Medical Help

Regulatory guidance explicitly mandates that immediate medical attention must be sought for any suspected overdose. Emergency services must be contacted if the individual is collapsed, having a seizure, or experiencing significant trouble breathing. The official protocol also requires contacting a poison control helpline for expert instruction. Management is defined as symptomatic and supportive treatment. Discontinuation of therapy is the initial step, followed by procedures such as activated charcoal and intensive hospital monitoring, including vital signs assessment and ECG. No specific antidote is known; treatment focuses on managing the documented life-threatening physiological effects.

Therapeutic Uses of Bisocor

Bisocor is a prescription medication utilized in the management of specific heart and circulatory conditions. The primary therapeutic domain is the management of hypertension (high blood pressure). It is also commonly used as part of a long-term treatment plan for stable chronic heart failure and to help manage the symptoms associated with angina pectoris (chest discomfort related to the heart).

The medication works to support heart function and assists in lowering elevated blood pressure. For patients, using Bisocor as prescribed helps to stabilize symptoms, such as reducing the frequency of chest pain episodes. This medication is typically part of a prescribed, long-term regimen to help support overall cardiovascular health.

Eligibility and Restrictions for Use

The eligibility for using Bisocor (Bisoprolol Fumarate) is defined by official regulatory documentation, which outlines populations for whom the medicine is permitted, restricted, or absolutely prohibited.

Eligibility scope Official Regulatory Status
Populations for whom use is allowed Adults with established cardiovascular conditions (e.g., hypertension, stable chronic heart failure).
Populations for whom use is not recommended Children and adolescents (under 18 years), as safety and efficacy have not been established. Pregnant women, with use restricted to cases where the benefit justifies the potential fetal risk.
Populations for whom use is contraindicated Patients with cardiogenic shock, overt cardiac failure, second- or third-degree AV block (without a pacemaker), or marked sinus bradycardia [Source 1.4]. Also, those with severe bronchial asthma or severe COPD [Source 1.1].

Condition-Based Eligibility Rules

  • Organ Impairment: Caution is required for patients with significant hepatic or renal impairment (e.g., creatinine clearance lt 40 mL/ min), as drug elimination may be slower [Source 3.1].
  • Diabetes: Use with caution is mandated as Bisocor may mask symptoms of hypoglycemia, such as tachycardia [Source 1.3].
  • Lactation: Use is a point of regulatory caution or is not recommended due to excretion into breast milk [Source 2.2].

Official regulatory documents establish clear boundaries that prohibit use in patients with specific severe conditions, and mandate caution or restriction for pediatric, pregnant, and organ-impaired populations.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Co-administration with other beta-blocking agents is contraindicated due to the risk of dangerously additive effects. High-risk combinations that are generally not recommended include calcium antagonists of the Verapamil-type and Diltiazem-type, and Class I antiarrhythmic drugs, as these agents can severely potentiate negative effects on heart contractility and atrioventricular (AV) conduction. The agents Floctafenine and Sultopride are also listed in regulatory documents as contraindicated combinations.

A documented pharmacokinetic interaction occurs with Rifampin, which increases the drug’s metabolic clearance, resulting in a shortened elimination half-life and reduced systemic exposure. Pharmacodynamically, non-steroidal anti-inflammatory drugs (NSAIDs) may reduce the overall hypotensive effect. Caution is also required with Digitalis glycosides and catecholamine-depleting drugs, as these may increase the risk of bradycardia.

A mandatory procedural rule exists for Clonidine: Bisocor must be discontinued several days before the withdrawal of Clonidine to reduce the risk of rebound hypertension. Regarding substances, food does not produce a clinically relevant interaction; however, alcohol may have additive effects in lowering blood pressure. Anaesthetists must also be aware of the beta-blockade prior to surgery due to the potential for interactions with anaesthetic agents.

Mechanism of Action

How Bisocor Works

Bisocor (Bisoprolol) modulates signaling within the sympathetic nervous system, targeting key mechanistic domains that influence beta1-adrenergic receptor activity and the renin-angiotensin-aldosterone system.


Selective beta1-Adrenergic Receptor Antagonism

Bisocor engages mechanisms involving receptor-mediated signaling by acting as a highly selective antagonist at beta1-adrenergic receptors, which are predominantly located in the cardiac tissue. This action directly suppresses signaling sequences initiated by endogenous catecholamines, leading to a reduction in the force of myocardial contraction (negative inotropic effect) and a slowing of the heart rate (negative chronotropic effect). This results in a reduction of sympathetic output to cardiac tissues.


Modulation of the Renin-Angiotensin System

The drug also influences systems where specific mediators regulate vascular and volume dynamics. By blocking beta1-receptors on the juxtaglomerular cells in the kidneys, Bisocor modifies early molecular steps that regulate the release of renin. Inhibiting renin release reduces the activation of the downstream renin-angiotensin-aldosterone cascade, thereby modulating peripheral vascular resistance and renal sodium reabsorption.

Dosage and Administration Information

How to Use Bisocor

Bisocor (Bisoprolol Fumarate) is a prescription-only medication administered via the oral route as a film-coated tablet. The tablets are typically taken once daily in the morning and may be administered with or without food. The tablets must be swallowed whole, though certain strengths are scored for division to aid in accurate dosing.

Official Dosing Regimens

The treatment schedules are determined by the condition being addressed:

Indication Standard Daily Dose Maximum Daily Dose
Hypertension/Angina Pectoris 10 mg (often started at 5 mg) 20 mg
Stable Chronic Heart Failure 10 mg (target dose) 10 mg

For stable chronic heart failure, treatment requires a structured, long-term titration phase. The regimen begins with a starting dose of 1.25 mg once daily, which is gradually increased over several weeks until the target 10 mg daily dose is reached, provided the patient tolerates the increase.

Special Procedural Conditions

If a dose is missed, it should be taken as soon as remembered, unless it is close to the next scheduled dose, in which case the missed dose is skipped; doses must not be doubled. For patients with severe renal or hepatic impairment, the dosage should not exceed 10 mg once daily. Use in the pediatric population is not recommended.

Importantly, treatment is a long-term therapy and must not be stopped suddenly. If the medicine must be discontinued, the dose should be reduced gradually over one to two weeks.

Recent Clinical Evidence

Bisocor: Recent Clinical Evidence

This summary outlines the types of official research studies that have been conducted for Bisocor (Bisoprolol Fumarate) across its approved uses, focusing only on how the evidence has been observed and what remains unclear.


Evidence for Use in Stable Chronic Heart Failure (HFrEF)

Large-scale, long-term Randomized Controlled Trials (RCTs) have monitored stable adult patients already receiving standard heart failure therapy. These studies primarily tracked outcomes related to systemic or functional imbalance, such as survival and the frequency of hospitalization due to heart failure worsening. Findings describe patterns observed in the studies over several years. The core evidence applies to stable populations; limited research exists for other types of heart failure.

Evidence for Use in Managing Hypertension and Stable Angina Pectoris

For Hypertension, research used short- to medium-term RCTs to track outcomes related to physiological strain, primarily monitoring changes in blood pressure and heart rate. Similarly, studies for Chronic Stable Angina Pectoris explored outcomes related to physical discomfort, examining the reported frequency of chest discomfort episodes and changes in exercise capacity. Comparative evidence explored whether findings were consistent with those reported for other classes of blood pressure medications.

Long-Term Research, Specific Populations, and Evidence Gaps

The follow-up periods reported in the research for heart failure are often multi-year, contrasting with the limited durations in many hypertension and angina trials. Research has explored the medicine in specific patient groups, including older adults and those with common comorbidities, but data for certain groups remain insufficient, particularly for pediatric populations. Research gaps exist regarding starting treatment during acute episodes of heart failure, and findings were mixed regarding specific subgroup responses across some indications.

Key Studies & References

  1. Bisoprolol improved endothelial function and myocardium survival of hypertension with stable angina: a randomized double-blinded trial
  2. Public Assessment Report (PAR) for Bisoprolol Fumarate - Indications for hypertension, angina pectoris, and stable chronic heart failure (Netherlands MEB/EU)

Frequently Asked Questions (FAQ)

Common questions about Bisocor (FAQ)


Q: How quickly should I expect Bisocor to start lowering my blood pressure?

A: Official information indicates that Bisocor is taken once daily, suggesting a sustained effect. While the medication's effects begin shortly after the first dose, the maximum blood pressure-lowering benefit often develops over several weeks of continuous use, according to clinical observation.

Q: Is it safe to drink coffee or caffeine while taking Bisocor?

A: Official regulatory documents do not specify a clinical interaction between Bisocor and caffeine. However, since caffeine can temporarily increase heart rate and blood pressure, it may oppose the intended effects of the medication. Patients are typically advised to monitor their caffeine intake, as stimulating beverages may oppose the desired heart and blood pressure effects of the medication.

Q: Can I take Bisocor with my other heart medications?

A: Caution is required when combining Bisocor with other heart medications. For example, co-administration with other beta-blockers or certain calcium channel blockers (like Verapamil or Diltiazem) is generally not recommended due to the risk of dangerously additive effects on the heart. It is necessary for the prescribing healthcare provider to be aware of all concurrent medications to manage the risk of adverse interactions.

Q: What are the most common reasons people stop taking Bisocor?

A: The decision to stop Bisocor is typically based on medical necessity or the development of intolerable side effects, such as persistent fatigue, severe dizziness, or a very slow heart rate. If discontinuation is necessary, official guidelines recommend a gradual reduction of the dose over one to two weeks, which should be done under the direction of a healthcare professional.

Q: Is it normal to feel a little dizzy when first starting Bisocor?

A: Yes, official safety information indicates that side effects like dizziness and headache are often reported and are typically more frequent when treatment is first started or when the dose is being changed. This feeling often subsides as your body adjusts to the medication.

Q: What should I do if my heart rate seems too slow while on Bisocor?

A: Bisocor is known to slow the heart rate (bradycardia), which is a very common side effect, especially in patients treated for heart failure. Symptoms related to a very slow heart rate, such as fainting or extreme dizziness, require prompt consultation with a healthcare provider for evaluation.

Q: Does Bisocor have a long-term impact on kidney function?

A: Bisocor is eliminated through the kidneys, and official documents note that patients with severe renal impairment may need careful monitoring and a reduced maximum dose. Official prescribing information does not describe a definitive long-term negative impact on kidney function when the medicine is used as directed.

Q: Is Bisocor safe for women who might become pregnant?

A: Official guidelines restrict the use of Bisocor during pregnancy, limiting it only to situations where the expected benefit is judged to outweigh the potential risk to the fetus. Consultation with a healthcare provider is required if pregnancy is planned or occurs while taking this medication.

Q: Can a person develop a tolerance to Bisocor over time?

A: Bisocor is intended for long-term use, particularly for chronic heart failure and hypertension, and studies have tracked patient outcomes over multiple years. Official regulatory documents do not specifically mention the development of clinical tolerance, or a loss of effectiveness, over these periods.

Q: What are the signs of a serious allergic reaction to Bisocor?

A: Official safety data lists hypersensitivity reactions, such as rash or itching, as rare side effects. Symptoms such as swelling of the face, tongue, or throat, or difficulty breathing, are signs of a severe allergic reaction and necessitate immediate emergency care.

Q: Can I take Bisocor at night instead of in the morning?

A: Official prescribing instructions typically state that Bisocor should be taken once daily in the morning. Since it is a long-acting medication, consistency in timing is important. Any decision to adjust the timing of the daily dose requires consultation with a prescribing clinician.

Q: What should I know about using Bisocor if I have diabetes?

A: If you have diabetes, regulatory information mandates caution when taking Bisocor because it may mask or hide some of the typical warning symptoms of low blood sugar (hypoglycemia), such as a rapid heartbeat (tachycardia). The prescribing clinician may advise closer monitoring of blood sugar levels.

Q: How does Bisocor affect exercise tolerance?

A: Bisocor reduces the heart's workload, which can affect the body's response to physical activity. Official studies on its use for stable angina pectoris included monitoring for changes in a patient's exercise capacity. Physical activity goals and their potential relationship to the medication should be reviewed by a healthcare provider.

Q: What is the expected long-term benefit of staying on Bisocor?

A: Clinical studies for heart failure have reported outcomes including improved survival and reduced frequency of hospitalization due to heart failure worsening. For hypertension and angina, the long-term benefit relates to sustained control of blood pressure, heart rate, and reduction in chest discomfort episodes.

Q: Does Bisocor cause dry mouth or increased thirst?

A: Official regulatory documents list common gastrointestinal side effects such as nausea, vomiting, and diarrhea. However, dry mouth or increased thirst are not typically cited as common or frequently reported side effects in the official safety profile for Bisocor.

Q: Is Bisocor known to interact with common pain relievers like ibuprofen?

A: Regulatory documents state that Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), which include common pain relievers like ibuprofen, may reduce the blood pressure-lowering effect of Bisocor. The prescribing clinician needs to be aware of all concurrent pain medications to monitor blood pressure effectively, due to the potential for reduced efficacy.

Q: Does taking Bisocor affect the ability to drive or operate machinery?

A: Because Bisocor can cause side effects like dizziness and tiredness, caution is advised. Official patient information indicates that operating a vehicle or machinery should be avoided until an individual is certain how this medication affects their coordination and concentration.

Q: How long does Bisocor stay in your system after taking it?

A: Bisocor has an elimination half-life that ranges from 9 to 12 hours in most healthy individuals. This means the concentration of the drug is reduced by half in that time. The medication is generally considered to be fully eliminated from the body after several half-lives have passed.

Q: Is Bisocor the same as carvedilol or metoprolol?

A: Bisocor (Bisoprolol) is a selective beta-1 blocker. While carvedilol and metoprolol are also beta-blockers, they are different medicines with distinct chemical structures and unique pharmacological properties that affect different receptors in the body.

Q: Are there different brand names for the medicine in Bisocor?

A: Yes, the active ingredient in Bisocor is Bisoprolol Fumarate. This medicine is also sold under other brand names, such as Zebeta and Concor, as well as under its generic name.

Q: Does Bisocor affect sleep patterns or cause insomnia?

A: Official safety data lists sleep disturbances, including the occurrence of nightmares, as a rare side effect associated with Bisocor use. Any persistent changes in sleep patterns should be reported to a healthcare provider.

Q: Does Bisocor have an effect on cholesterol levels?

A: Clinical trials reviewed in official prescribing documents for hypertension showed that Bisocor generally had a minimal effect on total serum cholesterol levels, with only small, clinically insignificant average changes observed compared to placebo.

Q: What kind of monitoring (e.g., blood tests) is needed while on Bisocor?

A: Routine monitoring while on Bisocor primarily involves checking blood pressure and heart rate. While rare changes in laboratory values like liver enzymes have been reported in studies, specific, regular blood testing is typically determined by the individual patient's clinical situation.

Q: Can Bisocor interact with common cold or flu medications?

A: Official warnings note that certain common cold and flu medications contain sympathomimetic agents (like decongestants), which can stimulate the nervous system. These agents may oppose the blood pressure-lowering effects of Bisocor. It is necessary to review the ingredients of over-the-counter products with a healthcare provider or pharmacist.

Q: What is the shelf life of Bisocor tablets?

A: The approved shelf life for Bisoprolol Fumarate tablets is typically 24 months, with some specific products having stability data supporting extensions up to five years. It should always be stored at room temperature, as specified on the packaging.

Q: Does Bisocor require a special diet to be most effective?

A: Official information confirms that Bisocor can be taken with or without food. While no specific restrictive diet is required for the medicine's effectiveness, a low-sodium diet is often a component of the overall management plan for blood pressure control.

Q: What happens to my body when I first start taking Bisocor?

A: When you first start Bisocor, it immediately begins to slow your heart rate and reduce the force of your heart's contractions. This reduction in the heart's workload can cause common initial side effects such as fatigue, headache, and dizziness, as your body adjusts to the change in blood flow and heart function.

Q: Are there any restrictions on alcohol consumption while taking Bisocor?

A: Official patient information advises that alcohol consumption should be avoided or severely limited. Alcohol can have additive effects, potentially increasing the blood pressure-lowering effect of Bisocor and worsening side effects like dizziness or fainting.

Q: Does Bisocor affect my mood or cause depression?

A: Regulatory documents list depression as a rare potential side effect of Bisocor. Any persistent changes in mood, including feelings of depression, should be reported to a healthcare provider.

How should Bisocor be stored and disposed of?

Official Storage Requirements

Bisocor (Bisoprolol Fumarate) tablets must be stored at Controlled Room Temperature, specifically between 20 C to 25 C (68 F to 77 F), though brief excursions are permitted up to 30 C (86 F). The medication must be kept in a closed container and protected from both excessive heat and moisture. It is strictly required that the tablets do not freeze.

Child Safety and Disposal

The product must be stored out of the sight and reach of children. For proper disposal of any unused or expired Bisocor, patients are directed to ask a healthcare professional or pharmacist for guidance. The medication should not be disposed of by flushing it down a toilet or pouring it into a drain unless a labeled instruction or a specific take-back program directs otherwise.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisocor found in:

A-Z Index: